Moderna could be on the verge of a breakthrough, but the biotech's MRNA cancer vaccine catalyst is overly priced in.

Proceeds to be utilized for general corporate purposes which may include the flexibility to invest in the growth of our ...

Moderna and Merck's wild gambit on a cancer vaccine appears to have worked, despite big doubts, logistical challenges, and ...

By Michael Erman and Julie Steenhuysen Aug 28 (Reuters) - Stephane Bancel, CEO of Moderna, was at a Lebanese restaurant ...

After years of layoffs, cash burn and political attacks on its core technology, Moderna’s melanoma vaccine data notched the ...

The biotech firm announced plans to raise $2 billion through convertible notes, which could be increased to $2.3 billion.

Prior to the melanoma outcome, indicators included an enrolled trial, a partner covering half the expenses, and a market that ...

CAMBRIDGE, MA / ACCESS Newswire / August 27, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and ...

The company’s fortunes cratered as demand for Covid-19 vaccines plummeted. But it was busy working on something else.

Moderna stock rallies as Wolfe Research upgrades it to "Peer Perform." But is there any further upside left in MRNA shares?

The biotech giant posted positive trial results of a cancer vaccine, boosting shares at a record-setting pace before ...

Merck and Moderna’s success with a personalized cancer vaccine designed to keep melanoma at bay opens a ​new avenue of ...